CA Patent

CA2819967C — Use of pirfenidone concomitantly with ciprofloxacin

Assigned to Intermune Inc · Expires 2016-03-22 · 10y expired

What this patent protects

The disclosure relates to improved methods and use of pirfenidone therapy when ciprofloxacin is administered concomitantly, such as use of a reduced dose of pirfenidone with a 750 mg twice daily dose of ciprofloxacin.

USPTO Abstract

The disclosure relates to improved methods and use of pirfenidone therapy when ciprofloxacin is administered concomitantly, such as use of a reduced dose of pirfenidone with a 750 mg twice daily dose of ciprofloxacin.

Drugs covered by this patent

Patent Metadata

Patent number: CA2819967C
Jurisdiction: CA
Classification: —
Expires: 2016-03-22
Drug substance claim: No
Drug product claim: No
Assignee: Intermune Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.